COMPANY PROFILE

Delfi Diagnostics

Explore full profile

Detects cancer early, when it is most curable, using high precision non-invasive blood tests

Baltimore, United StatesFounded 2019Biotech & Life Sciences

Valuation $1–2.5B Last recorded · 2022

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Delfi Diagnostics

Delfi Diagnostics is a cutting-edge startup that operates in the healthcare sector, specifically in the field of cancer detection. The company leverages advanced machine learning and a new field called fragmentomics to analyze fragments of cell-free DNA for early cancer detection. Unlike traditional screening methods that focus on known cancer-associated mutations, Delfi's technology scans millions of data points to identify previously unrecognized cancer-associated fragments. This innovative approach allows for a more comprehensive and potentially earlier detection of cancer.

The company's team is composed of leading experts in cancer biology, bioinformatics, machine learning, and public health. The CEO and founder, Dr. Victor Velculescu, is internationally recognized for his contributions to genomics and cancer research. The team's combined expertise and experience in various fields, including next-generation sequencing, bioinformatics, and regulated software development, position Delfi Diagnostics as a leader in the healthcare technology market.

Delfi Diagnostics' business model revolves around the development and commercialization of their novel healthcare technologies. The company generates revenue by offering their advanced cancer detection services to healthcare providers and patients. Their innovative approach to cancer screening has the potential to revolutionize the healthcare industry by providing a more efficient and effective method for early cancer detection.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Baltimore, United States
Employees: 159
Open positions: None listed
Dealroom signal: 65.1/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Tech for Biotech and Pharma, Tech for Hospitals and Clinics, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Jun 2024	$0	—	Merck & Co.	↗
SERIES BOther financing	Jul 2022	$225M	$900M	Menlo Ventures · Rock Springs Capital · Open Field Capital · Point72 Ventures	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Delfi Diagnostics website traffic

Latest recorded traffic for Delfi Diagnostics is 5.4K monthly website visits, up 3.8% over the last three months. Delfi Diagnostics's team declined 8.6% over the past year.

Latest monthly visits5.4K 3-month web change+3.8% 1-year team growth-8.6%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
STSoley TherapeuticsDrug discovery and development company using cellular responses and AI to identify novel therapies for complex diseases	Brentwood, United States	Operational	40	$290M	$800M
TDThrive Earlier DetectionDeveloping CancerSEEK, a blood-based test for early-stage cancer detection	Cambridge, United States	Acquired
ESExact SciencesDeveloper and manufacturer of cologuard, a non-invasive screening test for the early detection of colorectal cancer	Madison, United States	Acquired
INInterVennCombines next generation epiproteomics, instrumentation, and deep learning to augment cancer diagnosis, biomarker, and target discovery	South San Francisco, United States	Operational
PEPETsys ElectronicsDeveloping and producing gamma-ray detectors for the next generation of medical PET scanners	Oeiras, Portugal	Operational
PAPathXLWeb-based software solutions for digital pathology workflows	Belfast, United Kingdom	Acquired
RBRidge BiotechnologiesAI-enabled platform for precision enzyme and drug design	Palo Alto, United States	Operational
PHPhaseVUses advanced algorithms to optimize clinical trials, improving success rates, efficiency, and uncovering hidden signals in the data	Tel Aviv-Yafo, Israel	Operational